HIGH conviction · 13 dossiers

Q4 FY26 (2026-07-14) beat at $0.11 adj EPS vs $(0.01) est, but the re-rating driver is the FY27 revenue guide of $130-150M vs $85.1M consensus a 53-76% blowout that compresses ~65x trailing sales to ~15x forward. Stock gapped +29% to ~$93;…

EUV-monopoly narrative accelerating through the cleared 2026-07-16 Q2 binary: the guided-down quarter drew same-day target raises to $2,100–$2,500 (JPM, Wells, RBC), and ASML is pushing equipment price increases through TSMC resistance…

The June digestion resolved upward, not downward SNOW cleared the ~$244 June high and printed a fresh 52-week high at $284.99 before settling at $268.90 (2026-07-17). Q1 FY27 product revenue re-accelerated to +34% and the street is still…

A three-week sell-side upgrade cascade (Goldman $125→$142, JPM initiates OW $156, Citi/Melius Buy $156–$160, Barclays OW $145) plus a fuel-cost tailwind as the Hormuz crude spike unwinds has re-rated Allegiant's post-Sunseeker ULCC…

COMP006 Phase 3 in TRD read out positive on 2026-07-07 (26-week durability, 2027 launch reiterated), completing the pivotal package alongside COMP005 and triggering a same-week analyst upgrade cluster; the psychedelic-mental-health…

Small-cap Gulf Coast/Permian refiner re-rating on wide crack spreads plus a self-help restructuring (Enterprise Optimization Plan, DKL sum-of-parts). A four-firm analyst-target escalation from $58 to $73 in 19 days confirms an accelerating…

Fintech SMB-credit compounder on a beat-and-raise streak; four desks raised targets to $250–$280 in the two weeks into the ~2026-07-23 Q2 print while net charge-offs fell to 7.6% as the loan book scaled to a record $5.3B. Narrative…

Rare-disease platform re-rating on stacked de-risking: zilurgisertib FOP PDUFA set for 2026-09-26 after a 99.9% HO-lesion reduction, brelovitug HDV Phase 3 topline due 2H26, and Q1 sales +43% YoY with 2026 guide lifted to $660–680M. Six…

Roll-up compounder in clean momentum continuation: the sell-side is now chasing price, with KBW $80, Barclays $76 and Piper $75 targets (Jul 9-15) leapfrogging the old $60 consensus, while the Bright Point clearing bolt-on (2026-07-09)…

Agentic-AI trust-layer breakout confirmed and extending: NET holds above its reclaimed $256.79 ATH while the target cluster ran from $230–280 to $300–322 in eleven days (MS $322 on 2026-07-17) and market cap hit $101.16B. Cyber cohort…

AI-security spend narrative accelerating with third-party confirmation: IBM missed Q2 ($17.2B vs $17.86B) on 2026-07-14 and blamed budget migration into cybersecurity PANW +6.4%, CRWD +10%, BUG +6% same session. New ATH close $357.53…

The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus…

Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to…